Citius Oncology(CTOR)
$0.55-0.01 (-1.42%)
CTOR
Citius Oncology financials statements
$0.55
At close:-0.01 (-1.42%)
Want to see CTOR full AI Analyst Report?
Citius Oncology (CTOR) Ratios
132 Followers
Citius Oncology Ratios
CTOR's free cash flow for Q3 2026 was $-2.85M. For the 2026 fiscal year, CTOR's free cash flow was increased by $0.00 and operating cash flow was $-2.85M. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Sep 24 | Sep 23 | Sep 22 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 0.56 | 0.34 | 0.37 | 0.46 |
| Quick Ratio | 0.11 | 0.08 | 0.37 | 0.46 |
| Cash Ratio | 0.08 | 0.00 | 0.00 | 0.05 |
| Solvency Ratio | -0.44 | -0.55 | -0.57 | -0.85 |
| Operating Cash Flow Ratio | -0.11 | 0.00 | -0.03 | -0.01 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -28.53M | $ -27.26M | $ -14.46M | $ -3.73M |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.04 | 0.05 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.08 | 0.08 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.08 | 0.08 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.08 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.25 | 1.83 | 1.87 | 1.18 |
| Debt Service Coverage Ratio | -112.57 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -107.89 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.03 | 0.04 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.05 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.01 | -0.18 | 0.00 | 0.06 |
| Profitability Margins | ||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 104.46% | 102.80% | 104.75% | 111.86% |
| EBT Per EBIT | 100.77% | 100.00% | 100.00% | 100.00% |
| Return on Assets (ROA) | -24.53% | -25.07% | -26.60% | -12.73% |
| Return on Equity (ROE) | -55.19% | -45.84% | -49.72% | -14.98% |
| Return on Capital Employed (ROCE) | -45.72% | -39.82% | -45.42% | -13.18% |
| Return on Invested Capital (ROIC) | -45.72% | -39.82% | -45.42% | -13.18% |
| Return on Tangible Assets | -24.53% | -25.07% | -164.16% | -201.94% |
| Earnings Yield | -16.65% | -21.26% | -1.24% | -0.53% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | -0.07 | 0.00 | -0.01 | -0.00 |
| Free Cash Flow Per Share | -0.07 | 0.00 | -0.01 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -1373011.50 | 31588.25 | -150325.99 | 0.00 |
| Capital Expenditure Coverage Ratio | -1373011.50 | 31588.25 | -150325.99 | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.45 | 0.03 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -3.69% | 0.13% | -0.06% | -0.00% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -5.97 | -4.70 | -80.55 | -189.69 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.32 | 2.16 | 40.05 | 28.41 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -27.08 | 787.17 | -1700.91 | -21482.78 |
| Price-to-Operating Cash Flow Ratio | -27.08 | 787.14 | -1700.89 | -21483.67 |
| Price-to-Earnings Growth (PEG) Ratio | -0.45 | -0.08 | -0.54 | -0.03 |
| Enterprise Value Multiple | -6.33 | -5.02 | -84.37 | -212.13 |
| Enterprise Value | 148.61M | 103.26M | 1.02B | 1.03B |
| EV to EBITDA | -6.33 | -5.02 | -84.37 | -212.13 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -27.06 | 817.24 | -1700.86 | -21476.75 |
| EV to Operating Cash Flow | -27.06 | 817.22 | -1700.85 | -21477.64 |
| Tangible Book Value Per Share | 0.61 | 0.64 | -0.16 | -0.04 |
| Shareholders’ Equity Per Share | 0.61 | 0.64 | 0.29 | 0.40 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | -0.04 | -0.03 | -0.05 | -0.12 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.34 | -0.30 | -0.14 | -0.06 |
| Tax Burden | 1.04 | 1.03 | 1.05 | 1.12 |
| Interest Burden | 1.01 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.22 | -0.01 | 0.05 | 0.01 |
Currency in USD
